Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 207.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 386,523 shares of the biopharmaceutical company's stock after purchasing an additional 260,845 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.67% of Agios Pharmaceuticals worth $11,325,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of AGIO. Jefferies Financial Group Inc. acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $49,290,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $9,957,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $9,084,000. Deutsche Bank AG lifted its stake in shares of Agios Pharmaceuticals by 39.7% in the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after acquiring an additional 265,637 shares in the last quarter. Finally, Casdin Capital LLC acquired a new position in Agios Pharmaceuticals in the fourth quarter worth about $8,215,000.
Agios Pharmaceuticals Price Performance
Shares of NASDAQ AGIO traded up $0.07 during midday trading on Thursday, hitting $36.68. 243,705 shares of the company's stock were exchanged, compared to its average volume of 712,576. The stock's 50 day moving average price is $36.38 and its 200-day moving average price is $32.73. The firm has a market cap of $2.13 billion, a P/E ratio of 3.33 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The business had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.
Insider Transactions at Agios Pharmaceuticals
In other Agios Pharmaceuticals news, Director David Scadden sold 1,400 shares of the business's stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $40.00, for a total transaction of $56,000.00. Following the sale, the director directly owned 17,603 shares of the company's stock, valued at $704,120. The trade was a 7.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $92,905.80. Following the sale, the insider directly owned 26,122 shares in the company, valued at approximately $876,131.88. This trade represents a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,448 shares of company stock valued at $2,026,141 over the last three months. 4.30% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on AGIO shares. Scotiabank decreased their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research note on Monday, July 28th. Bank of America decreased their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $56.33.
Check Out Our Latest Research Report on AGIO
About Agios Pharmaceuticals
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Articles
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access